Pfizer has agreed to license three preclinical, in vivo CAR-T programs from China’s Starna Therapeutics, targeting autoimmune diseases. The deal marks Pfizer’s entry into in vivo CAR-T.
Starna will receive $330 million upfront and could earn up to $2.3 billion in development and commercial milestones, plus royalties on sales of approved products—bringing the headline potential value to about $2.6 billion.
Pfizer gets exclusive rights outside Greater China to develop, manufacture and commercialize the three programs. It will lead development in those territories and plans to make initial clinical-trial supplies at U.S. facilities.
The agreement also gives Pfizer rights to use Starna’s in vivo CAR-T technology in inflammation, immunology and oncology, plus options relating to additional compounds and Greater China rights.
The programs are still pre-IND, meaning they have not yet entered human trials. The deal is a high-stakes bet on an emerging approach, not evidence that the therapies are proven or near market.
Sources:
Pfizer Enters into Exclusive Licensing Agreement with Starna ...
Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China's ...
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal
Pfizer's Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
Pfizer Strikes $2.6 Billion Deal for Experimental Autoimmune Therapies
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
Pfizer enters in vivo CAR-T with $2.6B Starna deal
Pfizer enters exclusive licensing agreement with Starna Therapeutics
Pfizer Licenses Autoimmune Disease Programs From Starna In Deal Worth ...
Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B
Pfizer gets into in vivo CAR-T with up to $2.6B Chinese biotech licensing deal
Pfizer signs $2.6bn licensing agreement with Starna Therapeutics